{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:41Z","timestamp":1787020121754,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Medical Research Project of Chengdu Health Commission","award":["2022101"],"award-info":[{"award-number":["2022101"]}]},{"name":"the Technology Innovation Research and Development project of Chengdu Science and Technology Bureau","award":["2022-YF05-02139-SN"],"award-info":[{"award-number":["2022-YF05-02139-SN"]}]},{"name":"Key Research and Development Project of Science and Technology Department of Sichuan Province","award":["2023YFS0220"],"award-info":[{"award-number":["2023YFS0220"]}]},{"name":"the Medical Research Program of Sichuan Province","award":["S22042"],"award-info":[{"award-number":["S22042"]}]},{"name":"the National Key Research and Development Program of China","award":["2022YFC2304800"],"award-info":[{"award-number":["2022YFC2304800"]}]},{"name":"Beijing Hospital Management Center \"Dengfeng\" Talent Training Program","award":["DFL20221401"],"award-info":[{"award-number":["DFL20221401"]}]},{"name":"Beijing Municipal Health Commission High Level Public Health Talent Construction Project","award":["Discipline Leader 03-11"],"award-info":[{"award-number":["Discipline Leader 03-11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We sought to assess the factors influencing QTc interval prolongation in patients with multidrug- or rifampicin-resistant tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of admissions with multidrug-resistant or rifampicin-resistant tuberculosis as the primary diagnosis from nine regions in China between May 2018 and June 2020. Guided by directed acyclic graphs, we developed two multivariable logistic regression models to account for identified confounders and examine their impact on outcomes across different aspects. Results were represented as odds ratios with 95% confidence intervals. Statistical analysis was performed using RStudio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 1,421 patients included in the study, 1,293 (91.0%) had normal QTc intervals, while 128 (9.0%) exhibited prolonged QTc intervals. In treatment regimens-based adjusted models, treatment regimens containing bedaquiline and\/or linezolid, baseline QTc prolongation (\u2265\u2009450 ms), hypertension, and pre-treatment anemia were significantly associated with an increased risk of QTc interval prolongation. Comorbidity-based adjusted models showed that baseline QTc interval prolongation, hypertension, pre-treatment anemia, and adverse events during treatment including gastrointestinal reactions, liver and kidney injury, and electrolyte imbalances were strongly correlated with QTc interval prolongation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study demonstrates that baseline QTc prolongation, hypertension and choice of treatment regimens significantly increase the risk of QTc interval prolongation in patients with multidrug- and rifampicin-resistant tuberculosis. Additionally, adverse events during treatment further elevate this risk and require careful monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11896-1","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:25:29Z","timestamp":1765535129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors influencing QT interval prolongation during rifampicin-resistant tuberculosis treatment: a multicenter real-world study from China"],"prefix":"10.1186","volume":"26","author":[{"given":"Siyu","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingdong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanlin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenjie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"1","key":"11896_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00504-2","volume":"10","author":"K Dheda","year":"2024","unstructured":"Dheda K, Mirzayev F, Cirillo DM, Udwadia Z, Dooley KE, Chang KC, et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024;10(1):22.","journal-title":"Nat Rev Dis Primers"},{"key":"11896_CR2","unstructured":"WHO. Global tuberculosis report 2024. World Health Organization. 2024."},{"key":"11896_CR3","unstructured":"WHO. Global tuberculosis report 2014. World Health Organization. 2014."},{"key":"11896_CR4","unstructured":"WHO. Global tuberculosis report 2023. World Health Organization. 2023."},{"issue":"8","key":"11896_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.5588\/ijtld.22.0649","volume":"27","author":"MC Rikhotso","year":"2023","unstructured":"Rikhotso MC, Ledwaba SE, Ngandu JK, Mavumengwana V, Kinnear CJ, Warren R, et al. Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs. Int J Tuberc Lung Dis. 2023;27(8):599\u2013605.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"25","key":"11896_CR6","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"BT Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-week, all-oral regimen for Rifampin-resistant tuberculosis. N Engl J Med. 2022;387(25):2331\u201343.","journal-title":"N Engl J Med"},{"issue":"9190","key":"11896_CR7","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(99)02107-8","volume":"354","author":"S Viskin","year":"1999","unstructured":"Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354(9190):1625\u201333.","journal-title":"Lancet"},{"issue":"4","key":"11896_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.5588\/ijtld.14.0335","volume":"19","author":"E Harausz","year":"2015","unstructured":"Harausz E, Cox H, Rich M, Mitnick CD, Zimetbaum P, Furin J. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(4):385\u201391.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11896_CR9","doi-asserted-by":"publisher","unstructured":"Monedero-Recuero I, Hernando-Marrupe L, S\u00e1nchez-Montalv\u00e1 A, Cox V, Tommasi M, Furin J et al. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. Int J Tuberc Lung Dis. 2018. https:\/\/doi.org\/10.5588\/ijtld.18.0423.","DOI":"10.5588\/ijtld.18.0423"},{"issue":"6","key":"11896_CR10","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/cid\/ciac019","volume":"75","author":"C Hewison","year":"2022","unstructured":"Hewison C, Khan U, Bastard M, Lachenal N, Coutisson S, Osso E, et al. Safety of treatment regimens containing bedaquiline and delamanid in the EndTB cohort. Clin Infect Dis. 2022;75(6):1006\u201313.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"11896_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab413","volume":"8","author":"S Isralls","year":"2021","unstructured":"Isralls S, Baisley K, Ngam E, Grant AD, Millard J. Qt interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis under programmatic conditions: a retrospective cohort study. Open Forum Infect Dis. 2021;8(8):ofab413.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"11896_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.hroo.2024.03.007","volume":"5","author":"AB Anand","year":"2024","unstructured":"Anand AB, Malur K, Sabnis GR, Mahajan AU. A case series of drug-induced torsades de pointes in patients on multidrug-resistant tuberculosis treatment: beware the gift that conceals a blade. Heart Rhythm O2. 2024;5(5):324\u20136.","journal-title":"Heart Rhythm O2"},{"issue":"19","key":"11896_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","volume":"26","author":"SM Straus","year":"2005","unstructured":"Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, et al. Non-cardiac Qtc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26(19):2007\u201312.","journal-title":"Eur Heart J"},{"issue":"1","key":"11896_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/cid\/ciae601","volume":"81","author":"U Khan","year":"2025","unstructured":"Khan U, Rich M, Franke MF, Lachenal N, Ahmed S, Bekele A, et al. The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant\/rifampicin-resistant tuberculosis cohort. Clin Infect Dis. 2025;81(1):153\u20138.","journal-title":"Clin Infect Dis"},{"key":"11896_CR15","volume-title":"WHO operational handbook on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment, 2022 update","author":"WHO","year":"2022","unstructured":"WHO. WHO operational handbook on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022."},{"key":"11896_CR16","volume-title":"Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27\u201329 October 2020","author":"WH Organization","year":"2021","unstructured":"Organization WH. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27\u201329 October 2020. Geneva: World Health Organization; 2021."},{"issue":"2","key":"11896_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2353\/ajpath.2010.081068","volume":"177","author":"AM Cataldo","year":"2010","unstructured":"Cataldo AM, McPhie DL, Lange NT, Punzell S, Elmiligy S, Ye NZ, et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol. 2010;177(2):575\u201385.","journal-title":"Am J Pathol"},{"key":"11896_CR18","volume-title":"Measures for the ethical review of life sciences and medical research involving humans","author":"China NHCotPsRo","year":"2016","unstructured":"China NHCotPsRo. Measures for the ethical review of life sciences and medical research involving humans. Beijing, China: National Health Commission of China; 2016."},{"key":"11896_CR19","volume-title":"WHO consolidated guidelines on drug resistant tuberculosis treatment","author":"WH Organization","year":"2019","unstructured":"Organization WH. WHO consolidated guidelines on drug resistant tuberculosis treatment. Geneva: World Health Organization; 2019."},{"issue":"10","key":"11896_CR20","first-page":"733","volume":"42","author":"Association CSoToCM","year":"2019","unstructured":"Association CSoToCM. Chinese expert consensus on multidrug-resistant tuberculosis and Rifampicin-resistant tuberculosis treatment. Chin J Tuberc Respir Dis. 2019;42(10):733\u201349.","journal-title":"Chin J Tuberc Respir Dis"},{"issue":"1","key":"11896_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00001648-199901000-00008","volume":"10","author":"S Greenland","year":"1999","unstructured":"Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37\u201348.","journal-title":"Epidemiology"},{"issue":"5","key":"11896_CR22","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1183\/13993003.01552-2016","volume":"48","author":"M Tadolini","year":"2016","unstructured":"Tadolini M, Lingtsang RD, Tiberi S, Enwerem M, D\u2019Ambrosio L, Sadutshang TD, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, Delamanid and Clofazimine. Eur Respir J. 2016;48(5):1527\u20139.","journal-title":"Eur Respir J"},{"issue":"4","key":"11896_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4103\/0976-500X.195900","volume":"7","author":"JD Solanki","year":"2016","unstructured":"Solanki JD, Gadhavi BP, Makwana AH, Mehta HB, Shah CJ, Gokhale PA. QTc interval in young Gujarati hypertensives: effect of disease, antihypertensive monotherapy, and coexisting risk factors. J Pharmacol Pharmacother. 2016;7(4):165\u201370.","journal-title":"J Pharmacol Pharmacother"},{"key":"11896_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-017-0268-3","volume":"9","author":"XH Yang","year":"2017","unstructured":"Yang XH, Su JB, Zhang XL, Zhao LH, Xu F, Wang XQ, et al. The relationship between insulin sensitivity and heart rate-corrected QT interval in patients with type 2 diabetes. Diabetol Metab Syndr. 2017;9:69.","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"11896_CR25","first-page":"849","volume":"16","author":"W Lee","year":"2022","unstructured":"Lee W, Vandenberk B, Raj SR, Lee SS, Prolonged. QT Interval Cirrhosis: Twisting Time? Gut Liver. 2022;16(6):849\u201360.","journal-title":"QT Interval Cirrhosis: Twisting Time? Gut Liver"},{"issue":"1","key":"11896_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/0886022X.2019.1707098","volume":"42","author":"P Liu","year":"2020","unstructured":"Liu P, Wang L, Han D, Sun C, Xue X, Li G. Acquired long QT syndrome in chronic kidney disease patients. Ren Fail. 2020;42(1):54\u201365.","journal-title":"Ren Fail"},{"issue":"5","key":"11896_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/070674371506000502","volume":"60","author":"SW Rabkin","year":"2015","unstructured":"Rabkin SW. Impact of age and sex on QT prolongation in patients receiving psychotropics. Can J Psychiatry. 2015;60(5):206\u201314.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"11896_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33203-1","volume":"13","author":"AP Carll","year":"2022","unstructured":"Carll AP, Arab C, Salatini R, Miles MD, Nystoriak MA, Fulghum KL, et al. E-cigarettes and their lone constituents induce cardiac arrhythmia and conduction defects in mice. Nat Commun. 2022;13(1):6088.","journal-title":"Nat Commun"},{"key":"11896_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.drugalcdep.2015.07.019","volume":"155","author":"SR Moulin","year":"2015","unstructured":"Moulin SR, Mill JG, Rosa WC, Hermisdorf SR, Caldeira Lda C, Zago-Gomes EM. QT interval prolongation associated with low magnesium in chronic alcoholics. Drug Alcohol Depend. 2015;155:195\u2013201.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"11896_CR30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"11896_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/cpt.2685","volume":"112","author":"L Tanneau","year":"2022","unstructured":"Tanneau L, Karlsson MO, Rosenkranz SL, Cramer YS, Shenje J, Upton CM, et al. Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens. Clin Pharmacol Ther. 2022;112(4):873\u201381.","journal-title":"Clin Pharmacol Ther"},{"key":"11896_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2021.100216","volume":"23","author":"S Katrak","year":"2021","unstructured":"Katrak S, Lowenthal P, Shen R, True L, Henry L, Barry P. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. J Clin Tuberc Other Mycobact Dis. 2021;23:100216.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"3","key":"11896_CR33","first-page":"389","volume":"54","author":"I Darmayani","year":"2022","unstructured":"Darmayani I, Ascobat P, Instiaty I, Sugiri YJR, Sawitri N. Bedaquiline effect on QT interval of drugs-resistant tuberculosis patients: real world data. Acta Med Indones. 2022;54(3):389\u201396.","journal-title":"Acta Med Indones"},{"issue":"4","key":"11896_CR34","doi-asserted-by":"publisher","first-page":"e0104823","DOI":"10.1128\/spectrum.01048-23","volume":"11","author":"R Li","year":"2023","unstructured":"Li R, Ma JB, Yang H, Yang H, Yang XJ, Wu YQ, et al. Effects of bedaquiline combined with fluoroquinolone and\/or Clofazimine on QT interval in patients with Multidrug-Resistant tuberculosis: a retrospective study. Microbiol Spectr. 2023;11(4):e0104823.","journal-title":"Microbiol Spectr"},{"key":"11896_CR35","doi-asserted-by":"crossref","unstructured":"Choi PJ, Conole D, Sutherland HS, Blaser A, Tong AST, Cooper CB et al. Synthetic studies to help elucidate the metabolism of the preclinical candidate TBAJ-876-A less toxic and more potent analogue of bedaquiline. Molecules. 2020;25(6).","DOI":"10.3390\/molecules25061423"},{"issue":"9","key":"11896_CR36","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1128\/AAC.01723-10","volume":"55","author":"B Damle","year":"2011","unstructured":"Damle B, Labadie RR, Cuozzo C, Alvey C, Choo HW, Riley S, et al. Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation. Antimicrob Agents Chemother. 2011;55(9):4302\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"11896_CR37","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"11896_CR38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/thx.25.5.608","volume":"25","author":"AM Holmes","year":"1970","unstructured":"Holmes AM, Hesling CM, Wilson TM. Capreomycin-induced serum electrolyte abnormalities. Thorax. 1970;25(5):608\u201311.","journal-title":"Thorax"},{"issue":"5","key":"11896_CR39","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","volume":"43","author":"MP Mingeot-Leclercq","year":"1999","unstructured":"Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"11896_CR40","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/bcp.15587","volume":"89","author":"H Shao","year":"2023","unstructured":"Shao H, Shi D, Dai Y. Linezolid and the risk of QT interval prolongation: a pharmacovigilance study of the food and drug administration adverse event reporting system. Br J Clin Pharmacol. 2023;89(4):1386\u201392.","journal-title":"Br J Clin Pharmacol"},{"key":"11896_CR41","doi-asserted-by":"crossref","unstructured":"Li H, Salinger DH, Everitt D, Li M, Del Parigi A, Mendel C et al. Long-Term effects on QT prolongation of pretomanid alone and in combinations in patients with tuberculosis. Antimicrob Agents Chemother. 2019;63(10).","DOI":"10.1128\/AAC.00445-19"},{"issue":"4","key":"11896_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1742-7843.2012.00901.x","volume":"111","author":"J Klimas","year":"2012","unstructured":"Klimas J, Vaja V, Vercinska M, Kyselovic J, Krenek P. Discrepant regulation of QT (QTc) interval duration by calcium channel blockade and angiotensin converting enzyme inhibition in experimental hypertension. Basic Clin Pharmacol Toxicol. 2012;111(4):279\u201388.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"11896_CR43","first-page":"11","volume":"70","author":"A Kaur","year":"2022","unstructured":"Kaur A, Dhoat PS. Heart rate corrected QT interval and QT dispersion in patients with uncomplicated essential hypertension. J Assoc Physicians India. 2022;70(4):11\u20132.","journal-title":"J Assoc Physicians India"},{"key":"11896_CR44","doi-asserted-by":"publisher","DOI":"10.4103\/ijpvm.IJPVM_423_15","volume":"9","author":"JD Solanki","year":"2018","unstructured":"Solanki JD, Gadhavi BP, Makwana AH, Mehta HB, Shah CJ, Gokhale PA. Early screening of hypertension and cardiac dysautonomia in each hypertensive is needed-inference from a study of QTc interval in Gujarat, India. Int J Prev Med. 2018;9:62.","journal-title":"Int J Prev Med"},{"issue":"1","key":"11896_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijcard.2003.07.029","volume":"97","author":"C Passino","year":"2004","unstructured":"Passino C, Franzoni F, Gabutti A, Poletti R, Galetta F, Emdin M. Abnormal ventricular repolarization in hypertensive patients: role of sympatho-vagal imbalance and left ventricular hypertrophy. Int J Cardiol. 2004;97(1):57\u201362.","journal-title":"Int J Cardiol"},{"issue":"8","key":"11896_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183055","volume":"12","author":"JB Su","year":"2017","unstructured":"Su JB, Yang XH, Zhang XL, Cai HL, Huang HY, Zhao LH, et al. The association of long-term glycaemic variability versus sustained chronic hyperglycaemia with heart rate-corrected QT interval in patients with type 2 diabetes. PLoS ONE. 2017;12(8):e0183055.","journal-title":"PLoS ONE"},{"issue":"2","key":"11896_CR47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0002-9343(97)00027-2","volume":"103","author":"SM Haffner","year":"1997","unstructured":"Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med. 1997;103(2):152\u201362.","journal-title":"Am J Med"},{"issue":"11","key":"11896_CR48","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/eci.12673","volume":"46","author":"M Mizamtsidi","year":"2016","unstructured":"Mizamtsidi M, Paschou SA, Grapsa J, Vryonidou A. Diabetic cardiomyopathy: a clinical entity or a cluster of molecular heart changes? Eur J Clin Invest. 2016;46(11):947\u201353.","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"11896_CR49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1210\/jcem-64-4-751","volume":"64","author":"JK Kahn","year":"1987","unstructured":"Kahn JK, Sisson JC, Vinik AI. QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy. J Clin Endocrinol Metab. 1987;64(4):751\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"990","key":"11896_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/pgmj.2007.064048","volume":"84","author":"JM Pappachan","year":"2008","unstructured":"Pappachan JM, Sebastian J, Bino BC, Jayaprakash K, Vijayakumar K, Sujathan P, et al. Cardiac autonomic neuropathy in diabetes mellitus: prevalence, risk factors and utility of corrected QT interval in the ECG for its diagnosis. Postgrad Med J. 2008;84(990):205\u201310.","journal-title":"Postgrad Med J"},{"issue":"4","key":"11896_CR51","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/jdi.12772","volume":"9","author":"S Kobayashi","year":"2018","unstructured":"Kobayashi S, Nagao M, Asai A, Fukuda I, Oikawa S, Sugihara H. Severity and multiplicity of microvascular complications are associated with QT interval prolongation in patients with type 2 diabetes. J Diabetes Investig. 2018;9(4):946\u201351.","journal-title":"J Diabetes Investig"},{"issue":"12","key":"11896_CR52","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1253\/circj.CJ-18-0046","volume":"82","author":"IJ Kim","year":"2018","unstructured":"Kim IJ, Yang PS, Kim TH, Uhm JS, Pak HN, Lee MH, et al. Relationship between anemia and the risk of sudden cardiac arrest - a nationwide cohort study in South Korea. Circ J. 2018;82(12):2962\u20139.","journal-title":"Circ J"},{"issue":"11\u201312","key":"11896_CR53","first-page":"461","volume":"126","author":"M Stanojevi\u0107","year":"1998","unstructured":"Stanojevi\u0107 M, Stankov S. [Electrocardiographic changes in patients with chronic anemia]. Srp Arh Celok Lek. 1998;126(11\u201312):461\u20136.","journal-title":"Srp Arh Celok Lek"},{"issue":"1","key":"11896_CR54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1574886311207040262","volume":"11","author":"GA Keller","year":"2016","unstructured":"Keller GA, Alvarez PA, Ponte ML, Belloso WH, Bagnes C, Sparanochia C, et al. Drug-induced QTc interval prolongation: a multicenter study to detect drugs and clinical factors involved in every day practice. Curr Drug Saf. 2016;11(1):86\u201398.","journal-title":"Curr Drug Saf"},{"issue":"7","key":"11896_CR55","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0002-9149(03)00040-7","volume":"91","author":"F Roche","year":"2003","unstructured":"Roche F, Reynaud C, Pichot V, Duverney D, Costes F, Garet M, et al. Effect of acute hypoxia on QT rate dependence and corrected QT interval in healthy subjects. Am J Cardiol. 2003;91(7):916\u20139.","journal-title":"Am J Cardiol"},{"issue":"6","key":"11896_CR56","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.ekir.2024.03.007","volume":"9","author":"S Sasaki","year":"2024","unstructured":"Sasaki S, Fujisaki K, Nishimura M, Nakano T, Abe M, Hanafusa N, et al. Association between disturbed serum phosphorus levels and QT interval prolongation. Kidney Int Rep. 2024;9(6):1792\u2013801.","journal-title":"Kidney Int Rep"},{"issue":"8","key":"11896_CR57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474\u2013502.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"11896_CR58","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/cid\/ciad694","volume":"78","author":"L Mikiashvili","year":"2024","unstructured":"Mikiashvili L, Kempker RR, Chakhaia TS, Bablishvili N, Avaliani Z, Lomtadze N, et al. Impact of prior tuberculosis treatment with new\/companion drugs on clinical outcomes in patients receiving concomitant bedaquiline and delamanid for multidrug- and rifampicin-resistant tuberculosis. Clin Infect Dis. 2024;78(4):1043\u201352.","journal-title":"Clin Infect Dis"},{"key":"11896_CR59","doi-asserted-by":"publisher","unstructured":"Lodiong LJD, Izudi J, Amos T, Twinomugisha B, Kulaba N, Lumori BAE. HIV and body mass index are associated with prolonged QTc interval among people with drug-resistant tuberculosis on Bedaquiline-containing regimen in Uganda. IJID Reg. 2024;13;100438. https:\/\/doi.org\/10.1016\/j.ijregi.2024.100438.","DOI":"10.1016\/j.ijregi.2024.100438"},{"issue":"3","key":"11896_CR60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/FTD.0000000000001164","volume":"46","author":"AK Bhatnagar","year":"2024","unstructured":"Bhatnagar AK, Hemanthkumar AK, Muthu Vijayalakshmi M, Vohra V, Padmapriyadarsini C, Ramesh PM, et al. Effect of bedaquiline and delamanid pharmacokinetics on sputum culture conversion and adverse events in drug-resistant tuberculosis. Ther Drug Monit. 2024;46(3):363\u20139.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"11896_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106939","volume":"62","author":"Y Jin","year":"2023","unstructured":"Jin Y, Benkeser D, Kipiani M, Maranchick NF, Mikiashvili L, Barbakadze K, et al. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation. Int J Antimicrob Agents. 2023;62(4):106939.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"11896_CR62","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4314\/ejhs.v27i6.6","volume":"27","author":"J Ogunmodede","year":"2017","unstructured":"Ogunmodede J, Kolo P, Katibi I, Omotoso A. The use of first line highly active anti-retroviral therapy (HAART) is not associated with Qtc prolongation in HIV patients. Ethiop J Health Sci. 2017;27(6):613\u201320.","journal-title":"Ethiop J Health Sci"},{"issue":"14","key":"11896_CR63","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1097\/QAD.0000000000002327","volume":"33","author":"AD Knudsen","year":"2019","unstructured":"Knudsen AD, Kofoed KF, Gelpi M, Sigvardsen PE, Mocroft A, K\u00fchl JT, et al. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV. AIDS. 2019;33(14):2205\u201310.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11896-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:27:20Z","timestamp":1781627240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11896-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["11896"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11896-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the principles outlined in the Declaration of Helsinki and received approval from the Ethics Committee of the Public Health Clinical Center of Chengdu, which served as the leading institution (Approval No. YJ-K2022-81-01). The requirement for written informed consent to participate was waived by the same committee, because the study involved secondary analysis of pre-existing medical records, posed minimal risk to participants, and all data were anonymized prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}